|Day Low/High||2.08 / 2.17|
|52 Wk Low/High||1.29 / 4.84|
However, if the market doesn't have a steady uptick in the morning, bulls who bought in anticipation of positive seasonality may give up.
Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp.
In a new Phase III study, BRINAVESS TM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) (NYSE: MRK) and Cardiome Pharma...
Maurice Marciano sells 577,500 shares and Paul Marciano sells 200,000.
Several stocks trading near $5 were poised to move on above-average volume during Friday's session.
AMAG says it expects the FDA to make its approval decision on iron replacement therapy Feraheme within a few days.
Readers chime in on Hemispherx, Genxyme, ASCO, Cell Therapeutics and Cardiome.
Despite falling revenue and a lack of license fees during the quarter, the drug company's net loss narrowed.
King Pharmaceuticals bucks an otherwise dismal day in health stocks.
Drug company says "no" to Roche's advances, says make a better offer worth considering.
Shares of the company drop after announcing late-stage trial results that disappoint the Street.
The agency needs more info on irregular heart rhythm treatment vernakalant before it can consider approval.
King Pharma was among the health care-related stocks edging higher.
GE's deal with a Middle East sovereign wealth fund will lift the company's shares, Cramer says.
Cramer says the stock is OK and would buy it when it reaches $5.
It will move ahead with a phase III study of oral vernakalant using the 500-mg dose.
The CEO last week disclosed a regulatory hiccup in its application for Cleviprex, months after the FDA first informed the company of a delay.
Outlooks for SuperGen's Dacogen and Myriad Genetics' Flurizan; more Q&A on ImClone's Erbitux, and more.
A lack of resources leads the agency to push back drug approval deadlines, adding murkiness to an already tricky sector.
Onyx's increased spending is even more troubling than its failed Nexavar trial. Elsewhere, Genentech faces a key FDA decision.
Cardiome's radio silence on a delayed FDA decison is leaving many readers frustrated.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.